Skip to content
DataLookout
Menu

NCT03698019

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 448 versions: 19 with changes below, 31 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Oct 30, 2026 to Oct 30, 2027
  2. Minor Study completion date: Oct 30, 2026 to Oct 30, 2027
  3. Minor Study sites revised (815)
  4. Minor Study sites revised (815)
  5. Minor Study sites: 816 to 815v444
Show 15 earlier versionsHide 15 earlier versions
  1. Minor Study sites revised (816)v443
  2. Minor Study sites revised (816)v442
  3. Minor Study sites revised (816)v441
  4. Minor Study sites revised (816)v440
  5. Minor Study sites: 817 to 816v439
  6. Minor Study sites revised (817)v438
  7. Minor Study sites: 818 to 817v435
  8. Minor Study sites revised (818)v407
  9. Minor Study sites revised (818)v406
  10. Minor Study sites: 820 to 818
    • Study completion date: Oct 31, 2025 to Oct 30, 2026
    v405
  11. Minor Study sites revised (820)v404
  12. Minor Study sites revised (820)v402
  13. Minor Study sites revised (820)v401
  14. Minor Study sites revised (820)v400
  15. Minor Study sites revised (820)v399
  • Minor: routine updates

Endpoints

Primary

Two-Year Event-Free Survival Rate
Timeframe: 2 years

Secondary (4)

Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
Two-Year Overall Survival Rate
Response Rate
Number of Participants Receiving Surgery

Arms and interventions

Arm I (adjuvant pembrolizumab)Experimental

Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.

Arm II (adjuvant and neoadjuvant pembrolizumab)Active comparator

Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.

Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Therapeutic Conventional Surgery

Biologicals: Pembrolizumab

Sites

815 sites in 1 country